36,000 Shares in Clearside Biomedical, Inc. (NASDAQ:CLSD) Bought by International Assets Investment Management LLC

International Assets Investment Management LLC purchased a new stake in shares of Clearside Biomedical, Inc. (NASDAQ:CLSD) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 36,000 shares of the company’s stock, valued at approximately $57,000.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. JMP Securities reaffirmed a “market outperform” rating and set a $5.00 price objective on shares of Clearside Biomedical in a research report on Wednesday, March 13th. StockNews.com cut Clearside Biomedical from a “hold” rating to a “sell” rating in a research report on Friday, May 10th. Wedbush reissued an “outperform” rating and issued a $4.00 target price (down from $5.00) on shares of Clearside Biomedical in a research report on Wednesday, March 13th. HC Wainwright dropped their target price on Clearside Biomedical from $6.00 to $5.00 and set a “buy” rating on the stock in a research report on Monday, May 13th. Finally, Oppenheimer began coverage on Clearside Biomedical in a research report on Tuesday. They issued an “outperform” rating and a $5.00 target price on the stock. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $4.60.

Clearside Biomedical Stock Performance

Shares of Clearside Biomedical stock opened at $1.28 on Friday. The stock has a market cap of $95.65 million, a price-to-earnings ratio of -2.33 and a beta of 2.36. The stock has a 50 day moving average price of $1.28 and a 200-day moving average price of $1.33. Clearside Biomedical, Inc. has a one year low of $0.65 and a one year high of $2.12.

Clearside Biomedical (NASDAQ:CLSD) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03). The company had revenue of $0.23 million during the quarter, compared to the consensus estimate of $0.98 million. During the same period in the prior year, the firm posted ($0.15) EPS. Sell-side analysts predict that Clearside Biomedical, Inc. will post -0.63 earnings per share for the current fiscal year.

Clearside Biomedical Profile

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.